Autoimmune hemolytic anemia in a patient with myelodysplastic syndrome: Responding to 5-azacitidine therapy.

Kaur, Jaspreet; Tuler, Shahaf; Dasanu, Constantin A

Kaur, Jaspreet; Tuler, Shahaf; Dasanu, Constantin A.

Affiliation

Kaur J; Department of Medicine, Eisenhower Health, Rancho Mirage, CA, USA.
Tuler S; Department of Medicine, Eisenhower Health, Rancho Mirage, CA, USA.
Dasanu CA; Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.

J Oncol Pharm Pract ; 27(7): 1775-1778, 2021 Oct.

Article in En | MEDLINE | ID: mdl-33446051

Subject(s)

Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Myelodysplastic Syndromes; Pancytopenia; Aged; Anemia, Hemolytic, Autoimmune/diagnosis; Anemia, Hemolytic, Autoimmune/drug therapy; Azacitidine/therapeutic use; Female; Humans; Myelodysplastic Syndromes/complications; Myelodysplastic Syndromes/drug therapy

Key words

5-azacitidine; Myelodysplastic syndrome; autoimmune disorders; autoimmune hemolytic anemia; hypomethylating agent

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancytopenia / Autoimmune Diseases / Myelodysplastic Syndromes / Anemia, Hemolytic, Autoimmune Type of study: Diagnostic_studies Limits: Aged / Female / Humans Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2021 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google